Bevacizumab in the treatment of HER2-negative breast cancer

QR Code

Bevacizumab in the treatment of HER2-negative breast cancer

Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Be...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Vito Lorusso
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2008
Sujets:	Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/63902e14daea4d16883e5a78a2bcb251
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Current neoadjuvant treatment options for HER2 positive breast cancer
par: Abdel-Razeq H, et autres
Publié: (2011)

Bevacizumab in the treatment of ovarian cancer
par: Ramez N Eskander, et autres
Publié: (2011)

HER2 breast cancer therapies: a review
par: Conleth G Murphy, et autres
Publié: (2009)

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
par: Jia Li, et autres
Publié: (2009)

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
par: Shogo Nakamoto, et autres
Publié: (2021)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
par: Bella Kaufman, et autres
Publié: (2008)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
par: Toshiaki Utsumi, et autres
Publié: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
par: Abdel Kader Y, et autres
Publié: (2013)

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
par: Merel Gijsen, et autres
Publié: (2010)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
par: Mary F Mulcahy
Publié: (2008)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
par: Swanner J, et autres
Publié: (2015)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
par: Li J, et autres
Publié: (2017)

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
par: Sun JZ, et autres
Publié: (2014)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
par: Avisek Majumder, et autres
Publié: (2021)

Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells
par: Fekrazad R, et autres
Publié: (2011)

Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
par: Naruphontjirakul P, et autres
Publié: (2019)

Near-infrared quantum dots for HER2 localization and imaging of cancer cells
par: Rizvi SB, et autres
Publié: (2014)

Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer
par: Chen H, et autres
Publié: (2013)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
par: Nindo B. Punturi, et autres
Publié: (2021)

99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer
par: Rainone P, et autres
Publié: (2021)

Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment
par: Zheng D, et autres
Publié: (2020)

Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells
par: Shen Y, et autres
Publié: (2018)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
par: Laura Pizzuti, et autres
Publié: (2021)

Eribulin mesylate in the treatment of metastatic breast cancer
par: Jain S, et autres
Publié: (2012)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
par: Ho Hyun Ryu, et autres
Publié: (2021)

Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle
par: Zhang C, et autres
Publié: (2020)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
par: Advani P, et autres
Publié: (2015)

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer
par: Thomas Kunzke, et autres
Publié: (2021)

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
par: Board Editorial
Publié: (2021)

Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer
par: Rainone P, et autres
Publié: (2017)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
par: Gomari H, et autres
Publié: (2019)

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
par: Lin X, et autres
Publié: (2021)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
par: Jin X, et autres
Publié: (2020)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
par: Kanako Hagio, et autres
Publié: (2021)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
par: Chaturbhuj Agrawal, et autres
Publié: (2021)

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
par: Bernard Escudier, et autres
Publié: (2008)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
par: Yuefeng Wang, et autres
Publié: (2017)

Role of pertuzumab in the treatment of HER2-positive breast cancer
par: Hubalek M, et autres
Publié: (2012)

New developments in the treatment of HER2-positive breast cancer
par: Nahta R
Publié: (2012)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
par: Yalikong A, et autres
Publié: (2021)